Advertisement

Topics

Valeant Sells Obagi to Fund that Includes China Regenerative Medicine

03:23 EST 11 Nov 2017 | ChinaBio Today

Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to Haitong International Zhonghua Finance Acquisition Fund I, L.P. and its affiliate Obagi Cosmeceuticals, LLC. Obagi sells cosmeceuticals (skin care products that contain ingredients that have been proven to have a positive effect) through dermatologists or medical spas, although they are OTC products. One of the partners of the Haitong fund is China Regenerative Medicine International Limited, which presumably has an interest in marketing the Obagi products in China. More details....

Stock Symbols: (NYSE: VRX) (HK: 8158)

Share this with colleagues:

Original Article: Valeant Sells Obagi to Fund that Includes China Regenerative Medicine

NEXT ARTICLE

More From BioPortfolio on "Valeant Sells Obagi to Fund that Includes China Regenerative Medicine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...